Processa Pharmaceuticals, Inc. (PCSA)

US — Healthcare Sector
Peers: LIPO  SNTI  FENC  MNPR  PBLA  TPCS  GANX  LIXT  IMNM 

Automate Your Wheel Strategy on PCSA

With Tiblio's Option Bot, you can configure your own wheel strategy including PCSA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PCSA
  • Rev/Share 800.8979
  • Book/Share 392.2672
  • PB 0.0007
  • Debt/Equity 0.0042
  • CurrentRatio 3.4483
  • ROIC -2.1247

 

  • MktCap 14047399.0
  • FreeCF/Share -697.1434
  • PFCF -1.2942
  • PE -0.0003
  • Debt/Assets 0.0031
  • DivYield 0
  • ROE -3.4235

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 5
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Processa Pharmaceuticals Provides Portfolio and Business Update
PCSA
Published: July 01, 2025 by: GlobeNewsWire
Sentiment: Neutral

Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852 Continue enrolling patients in Phase 2 study of PCS6422 Strengthened balance sheet with $7M capital infusion VERO BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing next-generation cancer therapies, provides updates on its product pipeline, upcoming milestones and business activities.

Read More
image for news Processa Pharmaceuticals Provides Portfolio and Business Update
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering
PCSA
Published: June 17, 2025 by: GlobeNewsWire
Sentiment: Neutral

HANOVER, Md., June 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (the “Company”), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced the pricing of a public offering of 28,000,000 shares of common stock (or pre-funded warrants in lieu thereof), together with common warrants to purchase up to 28,000,000 shares of common stock at a combined public offering price of $0.25 per share (or pre-funded warrant in lieu thereof) and associated common warrant. The common warrants will have an exercise price of $0.25 per share, are exercisable upon issuance and will expire five years thereafter. …

Read More
image for news Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

About Processa Pharmaceuticals, Inc. (PCSA)

  • IPO Date 2014-03-07
  • Website https://www.processapharmaceuticals.com
  • Industry Biotechnology
  • CEO George K. Ng
  • Employees 10
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.